Inbox Robot: Amgen News http://www.inboxrobot.com/news/amgenConstantly updated news and information about a variety of topics. Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-… http://www.inboxrobot.com/news.php?fid=186697396 5 Sep 2008 18:02 GMT ... failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. This open-label Phase IIa clinical trial is designed to evaluate an intravenous formulation ... The Biggest News of the Day - Not Nokia Corporation, SanDisk Corp, Hoku Scientific Inc or Merrill Lynch & Co http://www.inboxrobot.com/news.php?fid=186695177 5 Sep 2008 17:34 GMT ... by the FDA for stronger warnings on certain arthritis drugs...companies mentioned include Abbott (ABT), Amgen (AMGN), and Wyeth (WYE)... into the need for tax credits for renewable energy... While those ... Option Skews - Visa Inc, Potash Corp. of Saskatchewan, Chesapeake Energy, CIENA Corp, Yahoo, eBay Inc, UST Inc http://www.inboxrobot.com/news.php?fid=186695176 5 Sep 2008 17:34 GMT ... eBay Inc (EBAY), General Electric (GE), Merrill Lynch & Co. (MER), General Motors (GM), Amgen Inc (AMGN), Toll Brothers (TOL), Fifth Third Bancorp (FITB), Sina Corp. (SINA), Juniper Networks (JNPR), Cypress ... Cytokinetics Announces the Initiation of Third Phase IIa Cli… http://www.inboxrobot.com/news.php?fid=186694558 5 Sep 2008 17:33 GMT ... failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. This open-label Phase IIa clinical trial is designed to evaluate an intravenous formulation ... Data Suggest CEL-SCI's CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis http://www.inboxrobot.com/news.php?fid=186694375 5 Sep 2008 17:33 GMT ... treatments comprise a $13 billion market. Enbrel, a leading rheumatoid arthritis treatment sold by Amgen and Wyeth, reported US sales in 2007 of about $3.2 billion. Enbrel is a ... Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-1827452 First Patient Dosed in a Clinical Trial Evaluating the Potential Effects of CK-1827452 on Cardiac Function, Hemodynamics and Oxygen Consumption http://www.inboxrobot.com/news.php?fid=186687360 5 Sep 2008 17:09 GMT ... failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. This open-label Phase IIa clinical trial is designed to evaluate an intravenous formulation ... FDA Orders Stronger Warnings on Arthritis Drugs http://www.inboxrobot.com/news.php?fid=186683039 5 Sep 2008 16:39 GMT ... is made by the drug company Centocor. Enbrel is marketed by the drug companies Amgen and Wyeth. ... A Pipeline Insight of the Cancer R&D Market: With a Focus on Lung, Brain, Head, Neck and Thyroid Tumors http://www.inboxrobot.com/news.php?fid=186681768 5 Sep 2008 16:37 GMT ... of NSCLC, particularly for those patients ineligible for Avastin (bevacizumab; Genentech/Roche) therapy. Vectibix (panitumumab; Amgen) and zalutumumab (HuMax-EGFR; Genmab/Medarex) show great promise to compete with Erbitux in the head ... --> Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-1827452 http://www.inboxrobot.com/news.php?fid=186678558 5 Sep 2008 16:09 GMT ... failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. This open-label Phase IIa clinical trial is designed to evaluate an intravenous formulation ... Cytokinetics Announces the Initiation of Third Phase IIa Clinical Trial of CK-1827452 http://www.inboxrobot.com/news.php?fid=186676533 5 Sep 2008 15:36 GMT ... failure. CK-1827452 is the subject of a Collaboration and Option Agreement between Cytokinetics and Amgen Inc. This open-label Phase IIa clinical trial is designed to evaluate an intravenous formulation ... FDA orders label changes on four TNF blockers http://www.inboxrobot.com/news.php?fid=186675772 5 Sep 2008 15:33 GMT ... The products in question are Johnson & Johnson/Schering-Plough's Remicade (infliximab), Abbott Laboratories' Humira (adalimumab), Amgen and Wyeth's Enbrel (etanercept) and UCB's Cimzia (certolizumab pegol). The FDA said that the ... FDA Wants Stronger Warnings On Arthritis Drugs http://www.inboxrobot.com/news.php?fid=186675560 5 Sep 2008 15:33 GMT ... companies. The stronger warnings need to be placed on arthritis and autoimmune drugs from Amgen, Wyeth, and Johnson & Johnson. This comes after fungal infections linked to the drugs ... 4 arthritis drugs must carry stronger warnings http://www.inboxrobot.com/news.php?fid=186648908 5 Sep 2008 13:05 GMT ... Chicago, Ill.-based Abbott Laboratories Inc; Cimzia by Belgium-based UCB; Enbrel by Thousand Oaks, Calif.-based Amgen Inc. and Madison, N.J.-based Wyeth; and Remicade by Horsham, Pa.-based Centocor, a unit of ... FDA orders stronger warnings for 4 rheumatoid arthritis drugs http://www.inboxrobot.com/news.php?fid=186645533 5 Sep 2008 12:50 GMT ... Chicago, Ill.-based Abbott Laboratories Inc; Cimzia by Belgium-based UCB; Enbrel by Thousand Oaks, Calif.-based Amgen Inc. and Madison, N.J.-based Wyeth; and Remicade by Horsham, Pa.-based Centocor, a unit of ... Kidney Research UK Launches First Ever National Kidney Disease Screening Pilot http://www.inboxrobot.com/news.php?fid=186640711 5 Sep 2008 11:30 GMT ... - People with hypertension The screening pilot, which is being sponsored by pharmaceutical companies Amgen and Roche, and supported by equipment from Siemens, is being launched because CKD affects ...